Amarin (AMRN) says Phase 3 trials for vascepa met primary efficacy endpoints and significantly...

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

Amarin (AMRN) says Phase 3 trials for vascepa met primary efficacy endpoints and significantly reduced median concentrations of large very-low-density lipoprotein, total LDL, small LDL and total high-density lipoprotein particles and reduced VLDL particle size in patients with very high triglycerides. Shares +1.7% AH.